XML 95 R46.htm IDEA: XBRL DOCUMENT
v3.25.4

Geographic and Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Schedule of Net Revenue by Operating Segments and Geographic Region | The following table presents net revenue by operating segment and geographic region (in thousands):
|  | 2025 |  | 2024 |  | 2023
Cardiopulmonary |  |  |  |  |  |
United States |  | $ | 275,859 |  |  | $ | 242,463 |  |  | $ | 202,358 |
Europe (1) |  | 201,044 |  |  | 168,024 |  |  | 157,414 |
Rest of World (1) |  | 308,482 |  |  | 273,025 |  |  | 244,340 |
|  | 785,385 |  |  | 683,512 |  |  | 604,112 |
Neuromodulation |  |  |  |  |  |
United States |  | 463,602 |  |  | 441,022 |  |  | 407,493 |
Europe (1) |  | 65,023 |  |  | 54,899 |  |  | 57,435 |
Rest of World (1) |  | 64,187 |  |  | 58,302 |  |  | 54,782 |
|  | 592,812 |  |  | 554,223 |  |  | 519,710 |
Other Revenue (2) |  | 9,856 |  |  | 15,702 |  |  | 29,723 |
Totals (3) (4) |  |  |  |  |  |
United States |  | 739,573 |  |  | 695,083 |  |  | 635,044 |
Europe (1) |  | 269,176 |  |  | 220,032 |  |  | 214,792 |
Rest of World (1) |  | 379,304 |  |  | 338,322 |  |  | 303,709 |
|  | $ | 1,388,053 |  |  | $ | 1,253,437 |  |  | $ | 1,153,545 |
(1)“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates. (2)“Other Revenue” includes revenue from the Company’s former ACS reportable segment, as discussed above, as well as rental and site services income not allocated to segments. (3)Net revenue to external customers includes $55.9 million, $48.9 million, and $41.5 million in the UK, LivaNova’s country of domicile, for the years ended December 31, 2025, 2024, and 2023, respectively. (4)No single customer represented over 10% of the Company’s consolidated net revenue. No country’s net revenue exceeded 10% of the Company’s consolidated revenue except for the U.S.
Schedule of Segment Reporting Information, by Segment | The following table presents a reconciliation of segment income to consolidated (loss) income before income tax (in thousands):
|  | 2025 |  | 2024 |  | 2023
Cardiopulmonary |  | $ | 108,301 |  |  | $ | 76,848 |  |  | $ | 26,407 |
Neuromodulation |  | 215,474 |  |  | 195,309 |  |  | 153,384 |
Segment income |  | 323,775 |  |  | 272,157 |  |  | 179,791 |
Other expense |  | (124,385) |  |  | (143,106) |  |  | (248,289) |
Operating income (loss) |  | 199,390 |  |  | 129,051 |  |  | (68,498) |
SNIA environmental liability expense |  | (365,553) |  |  | — |  |  | — |
Interest expense (1) |  | (49,286) |  |  | (63,070) |  |  | (58,853) |
Loss on debt extinguishment |  | (2,651) |  |  | (25,482) |  |  | — |
Foreign exchange and other income/(expense) |  | (2,681) |  |  | 47,811 |  |  | 46,125 |
(Loss) income before income tax |  | $ | (220,781) |  |  | $ | 88,310 |  |  | $ | (81,226) |
(1)Interest expense includes contractual interest expense associated with LivaNova’s short- and long-term financing arrangements and the amortization of debt discount and issuance costs of $23.1 million, $21.6 million, and $19.1 million for the years ended December 31, 2025, 2024, and 2023, respectively. The following table presents the components of segment income, including significant expenses, of LivaNova’s reportable segments (in thousands):
|  | Cardiopulmonary |  | Neuromodulation
|  | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023
Net revenue |  | $ | 785,385 |  |  | $ | 683,512 |  |  | $ | 604,112 |  |  | $ | 592,812 |  |  | $ | 554,223 |  |  | $ | 519,710 |
Less: |  |  |  |  |  |  |  |  |  |  |  |
Cost of sales |  | 381,710 |  |  | 334,326 |  |  | 306,359 |  |  | 55,819 |  |  | 50,236 |  |  | 50,213 |
Selling, general, and administrative |  | 225,257 |  |  | 199,747 |  |  | 191,571 |  |  | 202,596 |  |  | 187,649 |  |  | 175,273 |
Research and development |  | 65,739 |  |  | 52,904 |  |  | 45,255 |  |  | 118,923 |  |  | 121,029 |  |  | 140,840 |
3T litigation provision |  | 4,378 |  |  | 19,687 |  |  | 34,520 |  |  | — |  |  | — |  |  | — |
|  | $ | 108,301 |  |  | $ | 76,848 |  |  | $ | 26,407 |  |  | $ | 215,474 |  |  | $ | 195,309 |  |  | $ | 153,384 |
The following table presents assets by reportable segment (in thousands):
|  | December 31,
|  | 2025 |  | 2024
Cardiopulmonary |  | $ | 1,045,189 |  |  | $ | 900,672 |
Neuromodulation |  | 639,742 |  |  | 640,956 |
Other assets (1) |  | 921,122 |  |  | 964,761 |
|  | $ | 2,606,053 |  |  | $ | 2,506,389 |
(1)“Other assets” primarily include corporate assets not allocated to segments. The following table presents capital expenditures by segment (in thousands):
|  | 2025 |  | 2024 |  | 2023
Cardiopulmonary |  | $ | 44,506 |  |  | $ | 28,089 |  |  | $ | 22,367 |
Neuromodulation |  | 15,834 |  |  | 4,244 |  |  | 1,201 |
Other capital expenditures (1) |  | 23,863 |  |  | 17,621 |  |  | 11,539 |
|  | $ | 84,203 |  |  | $ | 49,954 |  |  | $ | 35,107 |
(1)“Other capital expenditures” primarily includes corporate capital expenditures not allocated to segments and capital expenditures of LivaNova’s former ACS reportable segment.
Schedule of Long-lived Assets by Geographic Areas | The following table presents property, plant, and equipment, net (1) by geographic region (in thousands):
|  | December 31,
|  | 2025 |  | 2024
United States |  | $ | 79,499 |  |  | $ | 65,170 |
Europe |  | 147,303 |  |  | 94,394 |
Rest of World |  | 15,801 |  |  | 10,696 |
|  | $ | 242,603 |  |  | $ | 170,260 |
(1)No country’s property, plant, and equipment, net exceeded 10% of LivaNova’s consolidated property, plant, and equipment, net except for the U.S. and Italy. Italian plant, property, and equipment, net included within Europe was $110.4 million and $73.7 million as of December 31, 2025 and 2024, respectively.

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration